← Back to Search

HPARSS Alert System for Childhood Cancer Survivors

N/A

Recruiting

Led By Robert J Hayashi, M.D.

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Treatment including chemotherapy and/or radiation therapy

Patients with a diagnosis of pediatric cancer (diagnosis at <18 years of age)

Must not have

Undergoing active cancer treatment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up to be completed at the time of enrollment completion (approximately 9 months)

Awards & highlights

No Placebo-Only Group

Summary

This trial will try to reduce barriers to prompt screening of sensory deficits in childhood cancer survivors using an electronic alert system.

Who is the study for?

This trial is for childhood cancer survivors aged 7-17, who finished treatment between 6 months and 2 years ago at Washington University School of Medicine. They must speak English and not have had sensory deficit screening or therapy before.

What is being tested?

The study tests a new system called HPARSS designed to help doctors identify kids at risk of sensory deficits after cancer treatment, prompting timely screening and intervention.

What are the potential side effects?

Since this trial involves screening rather than medication, there are no direct side effects from drugs. However, the process may cause anxiety or discomfort during testing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am receiving or have received chemotherapy or radiation therapy.

Select...

I was diagnosed with cancer before turning 18.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently receiving treatment for cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ to be completed at the time of enrollment completion (approximately 9 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~to be completed at the time of enrollment completion (approximately 9 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and to be completed at the time of enrollment completion (approximately 9 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Acceptability of HPARSS as measured by the Acceptability of Intervention Measure (AIM)

Feasibility of intervention as measured by Feasibility of Intervention Measure (FIM)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Patients: Highlighting Patients at Risk for Sensory Screening (HPARSS)Experimental Treatment1 Intervention

* The primary oncology team will utilize the HPARSS to identify patients who are at risk for sensory deficits based on prior treatment. The HPARSS will constitute a file of that will contain eligible patients based upon their past treatment and their corresponding risk for a particular sensory deficit based upon that treatment. The patient and parent/guardian will be approached to participate in the study. * Sensory deficit screening will be completed in the clinic and any screening results that indicate the need for referral for diagnostic testing or therapy will be scheduled by the primary treatment team staff.

Group II: Providers: Highlighting Patients at Risk for Sensory Screening (HPARSS)Active Control1 Intervention

-Providers will complete a survey regarding their views of the HPARSS. The Acceptability of Intervention Measure has 4 questions and the Feasibility of Intervention Measure has 4 questions.

0 / 3Eligibility criteria met